Last reviewed · How we verify
NNC 0142-0000-0002
NNC 0142-0000-0002 is a Small molecule drug developed by Janssen Research & Development, LLC. It is currently in Phase 2 development.
At a glance
| Generic name | NNC 0142-0000-0002 |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA) (PHASE2)
- Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NNC 0142-0000-0002 CI brief — competitive landscape report
- NNC 0142-0000-0002 updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI
Frequently asked questions about NNC 0142-0000-0002
What is NNC 0142-0000-0002?
NNC 0142-0000-0002 is a Small molecule drug developed by Janssen Research & Development, LLC.
Who makes NNC 0142-0000-0002?
NNC 0142-0000-0002 is developed by Janssen Research & Development, LLC (see full Janssen Research & Development, LLC pipeline at /company/johnson-johnson).
What development phase is NNC 0142-0000-0002 in?
NNC 0142-0000-0002 is in Phase 2.
Related
- Manufacturer: Janssen Research & Development, LLC — full pipeline
- Compare: NNC 0142-0000-0002 vs similar drugs
- Pricing: NNC 0142-0000-0002 cost, discount & access